Abstract
BackgroundThe NSD family of histone lysine methyltransferases have emerged as important biomarkers that participate in a variety of malignancies. Recent evidence has indicated that somatic dysregulation of the nuclear receptor binding SET domain-containing protein 1 (NSD1) is associated with the tumorigenesis in HCC, suggesting that NSD1 may serve as a prognostic target for this malignant tumor. However, its mechanism in human hepatocellular carcinoma (HCC), the major primary malignant tumor in the human liver, remains unclear. Hence, we investigated how NSD1 regulated HCC progression via regulation of the Wnt/β-catenin signaling pathway.MethodsReverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western blot analysis was performed to identify the expression of NSD1 in HCC cells and clinically obtained tissues. The relationship between NSD1 expression and prognosis was analyzed by Kaplan-Meier survival curve. Further, a NSD1 knockout cell line was constructed by CRISPR/Cas9 genomic editing system, which was investigated in a battery of assays such as HCC cell proliferation, migration and invasion, followed by the investigation into NSD1 regulation on histone H3, Wnt10b and Wnt/β-catenin signaling pathway via ChIP. Finally, a nude mouse xenograft model was conducted in order to assess tumorigenesis affected by NSD1 knockout in vivo.ResultsNSD1 was overexpressed in HCC tissues and cell lines in association with poor prognosis. Knockout of NSD1 inhibited the proliferation, migration and invasion abilities of HCC cells. CRISPR/Cas9-mediated knockout of NSD1 promoted methylation of H3K27me3 and reduced methylation of H3K36me2, which inhibited Wnt10b expression. The results thereby indicated an inactivation of the Wnt/β-catenin signaling pathway suppressed cell proliferation, migration and invasion in HCC. Moreover, these in vitro findings were reproduced in vivo on tumor xenograft in nude mice.ConclusionIn conclusion, the study provides evidence that CRISPR/Cas9-mediated NSD1 knockout suppresses HCC cell proliferation and migration via the NSD1/H3/Wnt10b signaling pathway, suggesting that NSD1, H3 and Wnt10b may serve as potential targets for HCC.
Highlights
The nuclear receptor binding SET domain (NSD) family of histone lysine methyltransferases have emerged as important biomarkers that participate in a variety of malignancies
Our results revealed that nuclear receptor binding SET domain-containing protein 1 (NSD1) was overexpressed in hepatocellular carcinoma (HCC) (Fig. 1a)
We assessed survival by a Kaplan-Meier survival curve, and were able to further confirm that patients with NSD1 overexpression did go on to show poor prognosis (Fig. 1c). These aforementioned results demonstrate that NSD1 is overexpressed in HCC, and this overexpression is closely associated with poor prognosis
Summary
The NSD family of histone lysine methyltransferases have emerged as important biomarkers that participate in a variety of malignancies. Clustered regularly interspaced short palindromic repeats/CRISPR-associated 9 (CRISPR/Cas9) mediated genome-editing is an effective approach towards introducing mutations with a single sgRNA guide or generating knockout of genomic fragment with two or more sgRNA guides in human cells, which is widely applied to understand gene function and molecular mechanisms underlying diseases [10]. Winglessrelated mouse mammary tumor virus integration site 10b (Wnt10b) is a member of the Wnt ligand gene family, which can activate the Wnt/β-catenin signaling pathway and plays a regulatory role in cell differentiation, proliferation and tumorigenesis in HCC [14, 15]. This study attempts to provide theoretical support for the diagnosis and treatment of HCC by investigating the regulatory NSD1/H3/Wnt10b signaling pathway in HCC cell proliferation, migration and invasion
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Experimental & Clinical Cancer Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
